Navigation Links
Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinson's Disease
Date:7/1/2010

me. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform, including treatment of Parkinson's disease. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in Sangamo's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Vista Partners announced today that it has ... "Company") and raised its twelve month target price to AUD ... is on track to enter clinical trials for its AMI ... The Company recently completed humanisation of its "first in class" ...
... of brand drug "copay coupon" promotions, which lure insured ... costs by $681 million in Missouri over the next ... to new research from Visante and released by the ... of these promotions by state and local government workers ...
Cached Medicine Technology:Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $681 Million in Missouri 2
(Date:4/15/2014)... a decades-old medical mystery and in the process have ... infections, which kill about 1.5 million people a year. The ... amphotericin, an antifungal drug that has been in use for ... as toxic to human cells as it is to the ... new findings appears in Nature Chemical Biology . , ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... IL A new study shows that moderate to ... increased risk of stroke, cancer and death. , Results ... moderate to severe obstructive sleep apnea were four times ... four times more likely to have a stroke (HR ... cancer (HR = 3.4), and 2.5 times more likely ...
(Date:4/14/2014)... involving serious youth offenders, the answer to one open-ended question ... "How long do you think you,ll live?", According to the ... time., Author Dr. Alex Piquero said the study found those ... offend at very high rates and commit more serious offenses, ... in life offend much less., "In a lot of distressed ...
(Date:4/14/2014)... Depression can hit young fathers hard -- with symptoms increasing ... children,s lives, a new Northwestern Medicine study has found. , ... first five years of fatherhood for these young men, who ... whom lived in the same home as their children. The ... journal Pediatrics . , This study is the first ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2
... 14 Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ... Drug,Administration (FDA) has granted final approval for the ... Tablets, "over-the-counter", (OTC), 5 mg and 10 mg ... be marketed as two separate OTC,products in two ...
... widens, the concerns about oversight deepen , , , First ... ever before, Americans are worried about the safety of the ... reason. , In little less than a year and a ... own peculiar food pyramid: meats, vegetables, salad, snacks, fast food, ...
... from Life Coach Laura Berman Fortgang -, NEW YORK, ... fresh starts and changing for the better. Internationally recognized,life coach, ... resolutions and stick with them throughout the year. With Laura,s,tips ... is,sure to start brightly., "Make a New Year,s resolution ...
... the sound they make is an important survival skill and ... objects can physically make very dissimilar sounds and we are ... source of the sound. Scientists funded by the Biotechnology and ... human ear and the brain come together to help us ...
... LDL levels influence heart disease risk , , SUNDAY, Jan. ... which influence the risk of heart disease, have been ... in three countries. , "I would predict that some ... drugs," said the study,s senior author, Goncalo Abecasis, an ...
... "Without notMYkid, I,wouldn,t be here today," says James, ... didn,t know, as long as I was at dinner ... share my story,with kids today and prevent them from ... thrilled that a partnership between Chrysler LLC and,Barrett- Jackson ...
Cached Medicine News:Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Children's Zyrtec(R) Chewable Tablets for Allergy Relief and Children's Zyrtec(R) Chewable Tablets for Hives Relief 2Health News:U.S. Food Safety: Home-Grown Problems Abound 2Health News:U.S. Food Safety: Home-Grown Problems Abound 3Health News:U.S. Food Safety: Home-Grown Problems Abound 4Health News:U.S. Food Safety: Home-Grown Problems Abound 5Health News:U.S. Food Safety: Home-Grown Problems Abound 6Health News:Smile! Make Your New Year's Resolutions a Reality This Year 2Health News:Smile! Make Your New Year's Resolutions a Reality This Year 3Health News:Lend me your ears -- and the world will sound very different 2Health News:Seven New Cholesterol Genes Discovered 2Health News:Seven New Cholesterol Genes Discovered 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: